We aimed to describe rotavirus epidemiology and clinical findings including extraintestinal manifestations in a setting that has yet to introduce rotavirus vaccines in the national immunization program. A literature search was performed by using the key words "Turkey" and "rotavirus." Ninety-eight studies published between 1987 and 2016 including epidemiological, clinical, and genotypical data at least 1 year duration were included. There were a total of 117 741 children with diarrhea and 26 566 rotavirus gastroenteritis with a median detection rate 31.8% (95% CI, 31.3-32.4) under 5 years of age. The rate of dehydration was 47% (95% CI, 23.4-91.6). There were 328 cases reported to be presenting with a various complication related to rotavirus in 2750 children in eight studies. The overall complication rate was 11.7% (95% CI, 10.7-12.9). The cumulative incidence of the most common genotyp- Studies carried out outside of Turkey, case reports, and studies in turkeys or in other animals, irrelevant with key words, were excluded.
Summary
We aimed to describe rotavirus epidemiology and clinical findings including extraintestinal manifestations in a setting that has yet to introduce rotavirus vaccines in the national immunization program. A literature search was performed by using the key words "Turkey" and "rotavirus. 
| INTRODUCTION
Rotavirus is the most common cause of severe, acute gastroenteritis in infants and children worldwide. 1 Rotavirus is thought to be a cause of systemic disease, but the exact incidence of extraintestinal manifestations of rotavirus infections remains unclear. 2 There are more than 215 000 deaths per year among young children that have been associated with rotavirus, disproportionately high levels of mortality in Asia and sub-Saharan Africa. 3 Two rotavirus vaccines, monovalent (RV1) and pentavalent (RV5),
were approved for preventing rotavirus diarrhea and licensed in many countries. The data about the efficacy and effectiveness for both vaccines provided evidence to conclude that they are efficacious and effective in preventing severe rotavirus gastroenteritis (RVGE) and rotavirus deaths in children aged less than 5 years in both developed and developing countries. 4 The Studies carried out outside of Turkey, case reports, and studies in turkeys or in other animals, irrelevant with key words, were excluded.
Articles of outbreaks, letters to editor, vaccines and cost-effectiveness studies, and studies with duration of less than 1 year and without original data were also excluded. These are shown in Figure 1 .
| Screening and data extraction
Papers were screened based on the titles and abstracts by four researchers. Full-text versions were obtained for potentially eligible studies. Four independent researchers assessed the full text to confirm whether they met the inclusion criteria. Data were extracted by the researchers who assessed the full texts using a predefined Microsoft Office Excel database.
FIGURE 1
Flow of information through the phases of the systematic review. A literature search was performed by using the key words "Turkey" and "rotavirus." Ninety-eight studies published between 1987 and 2016 including epidemiological, clinical, and genotypical data at least 1 year duration were included
| Statistical analysis
Chi-squared test of heterogeneity (Cochran's Q) calculated the I 2 statistic and its 95% uncertainty interval; this was also done for the second analysis of prevalence. Subgroups of data estimating, prevalence of RVGE, complications, and genotypes, were analyzed using the random effects models (I 2 > 50%), with an assumption of heterogeneity of true prevalence across study populations, using the Stata statistical software package (version 8.0, Stata Corporation, College Station, TX). All statistical hypothesis tests were carried out at the two-sided 0.05 level of confidence.
| RESULTS
The literature search identified 573 records from electronic databases.
After titles and abstracts is screened, 98 articles were selected for inclusion criteria ( Figure 1 ). Of the 98 publications, which data were abstracted, 66 contained only epidemiological data, 21 contained clinical data in addition to epidemiological data, seven contained genotypical data in addition to epidemiological data, and four contained clinical and genotypical data in addition to epidemiological data. All the studies were published between 1987 and 2016.
There were a total of 117 741 children with diarrhea and 26 566 RVGE in these studies. IC (64.5%), LA (13.3%), ELISA (16.7%), ELISA and LA (2.2%), or RT-PCR (3.3%) were the techniques that were used for detection of rotavirus in the stool in the studies included in this review. Rotavirus was investigated only in children with diarrhea.
Rotavirus infection was prevalent throughout the year with a peak incidence during winter. There was a heterogeneity among age groups in most of the studies, so the detection rate of rotavirus among age groups and the age distribution of children with RVGE could be calcu- Table 2 in detail.
There were 11 studies examining the distribution of rotavirus genotypes circulating in Turkey. Two of them reported only G and P genotypes, and nine studies reported G and P combinations. Genotyping was done by PCR in all studies. G/P combinations and predominant rotavirus strains are shown in Table 3 
| DISCUSSION
In Turkey, rotavirus is the most important pathogen causing gastroenteritis in children like in other parts of the world. 104 According to the results of this study, epidemiological pattern of disease shares similarities with both developed and developing countries. Although age distribution was not established in all studies, most cases (>50%) were less than 2 years of age, and among them, most were (>50%) less than 1 year of age. This is consistent with the rates reported in Asia and Africa where the most of deaths occur attributed to RVGE. 3 Since these children are more vulnerable to severe disease, vaccination is important to protect them. On the other hand, seasonality of rotavirus infection in this study is similar to developed countries 105 with a peak incidence during winter despite the disease is prevalent throughout the year. Rotavirus detection rate is similar to other parts of the world. 104 We could not make any conclusion about the burden of disease because almost all the studies in this review were laboratory based reporting the detection rate of rotavirus in children with gastroenteritis.
As a result of evaluation of studies, which could assign G/P combinations, the cumulative incidence of the most common combinations circulating worldwide was found to be only 59 respectively. There was a diversity of rotavirus genotypes, and a variety of unusual rotavirus strains was also identified. This is a similar pattern observed in developing countries where the effectiveness of rotavirus vaccines is lower than the developed countries. 4 These results emphasize the evolving nature of rotaviruses and may be important while evaluating the heterotypic protection of vaccines. analysis and reviews about RVGE in the literature only included epidemiological and genotypical data. [112] [113] [114] [115] [116] Therefore, the exact incidence of these complications is unknown. Several limitations must be considered both for our study and for previous clinical studies.
On the basis of the retrospective pattern of the classical systematic review, we could not make any conclusion whether these complica- Strain diversity might have also played an important role in the clinical presentation of RVGE in children in Turkey. In a recent study, it was indicated that host genetic susceptibility to norovirus and rotavirus infection may be strain specific. 117 The authors mentioned that difference in strain distribution and the proportion of presentation in children reported to be presenting with a complication related to rotavirus in our study.
In conclusion, results of this study presenting that rotavirus is not only a cause of gastroenteritis but also a systemic disease as well would make sense that benefits of rotavirus vaccines may be higher than that is predicted. As our knowledge about clinical presentations of rotavirus infections increases, our understanding of vaccine effectiveness and cost analysis will improve. So, to understand the true performance of rotavirus vaccination programs, detailed databases recording both circulating genotypes and clinical presentations are needed besides the development of robust regional surveillance systems that can provide comprehensive and systematic data on disease burden. 
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